Frekil

Executive Summary

Frekil is a YC X25-backed seed-stage startup building an AI-powered SaaS platform to automate real-world evidence (RWE) generation for pharma and biotech — a genuinely large, fast-growing market ($4.74B in 2024, 14.8% CAGR) with strong regulatory tailwinds from FDA's 2024-2025 guidance updates. The core product thesis — architectural separation of AI and clinical data with automated OMOP CDM mapping and end-to-end TFL generation — addresses a real workflow gap that incumbents have not fully solved. However, the company is extremely early (founded 2025, 2 employees, $500K pre-seed, no verifiable paying customers), and neither founder has a background in regulatory affairs, biostatistics, or pharma — a meaningful credibility gap when selling into risk-averse enterprise pharma buyers who need to trust your tool before submitting evidence to the FDA. The single biggest risk is that the pharma enterprise sales cycle (12–24+ months) will exhaust the current runway long before Frekil can build the regulatory proof points, domain credibility, and customer base needed to reach Series A metrics.